Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Deferred Revenue: 2015-2023

Historic Current Deferred Revenue for Cartesian Therapeutics (RNAC) over the last 9 years, with Dec 2023 value amounting to $5.8 million.

  • Cartesian Therapeutics' Current Deferred Revenue fell 95.77% to $412,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $412,000, marking a year-over-year decrease of 95.77%. This contributed to the annual value of $5.8 million for FY2023, which is 886.34% up from last year.
  • According to the latest figures from FY2023, Cartesian Therapeutics' Current Deferred Revenue is $5.8 million, which was up 886.34% from $593,000 recorded in FY2022.
  • Cartesian Therapeutics' Current Deferred Revenue's 5-year high stood at $110.8 million during FY2020, with a 5-year trough of $593,000 in FY2022.
  • Its 3-year average for Current Deferred Revenue is $23.9 million, with a median of $5.8 million in 2023.
  • As far as peak fluctuations go, Cartesian Therapeutics' Current Deferred Revenue crashed by 99.09% in 2022, and later surged by 886.34% in 2023.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Current Deferred Revenue stood at $16.4 million in 2019, then skyrocketed by 577.49% to $110.8 million in 2020, then tumbled by 41.06% to $65.3 million in 2021, then slumped by 99.09% to $593,000 in 2022, then spiked by 886.34% to $5.8 million in 2023.